THE AGENDA AFRICA NOW - Galien Foundation€¦ · Over the years they Participated in the Elie Wiesel Foundation’s Conferences: NObEl lAUREATEs Peter Agre (Chemistry, 2003) Zhores

AFRICA NOW

DAKAR – SENEGAL NovEmbER, 27 & 28, 2o18

PRIX GALIEN INTERNATIONALGALIEN FoRUm

THE AGENDA

www.prix-galien-international.org

Innovation to improve the Human Condition.

Macky SallPresident of Senegal

The Republic of Senegal is pleased to welcome you to Dakar No-vember 27 and 28, 2018 for the Prix Galien International and the Galien Forum, organized for the first time in Africa. Many personalities, leading experts, practitioners, and researchers from across the globe, including Nobel Prize winners in medicine, will take part.

Holding these events on Senegalese soil complements focused national efforts to augment our contributions to domestic and international public health. We believe that in addition to education, health-a cornerstone of prosperity and innova-

tion-must remain at the heart of public policies.

Indeed, education, and the training of quality care providers and administrators are inextricably linked. The development of knowledge and know-how is the basis of scientific progress, including in the fields of medical, pharmacological, and biotechnical sciences.

For this reason, ongoing commitments are critical to raising awareness and motivating young people to engage in science. Such commitments pave the way for the progress and well-being of humanity.

And it is this vocation that we want to nurture and invigorate by welcoming the Prix Galien Inter-national and the Galien Forum.

Moreover, we live in a world where rapid cross-border transport and globalization are transforming local public health issues into global epidemics. The HIV/AIDS, Ebola, Zika virus, and SARS epidemics serve as stark examples. Pandemic preparedness must be supported in a comprehensive and integrated way. Working together to address threats that face us all is essential.

This is what the Prix Galien has done since 1970, by promoting the research and development of innovative health technologies, such as drugs, vaccines, and diagnostics. As such, I would like to warmly thank Mrs. Marion Wiesel, President of the Elie Wiesel Foundation for Humanity for her support of this important initiative.

I invite all participants to leverage the unique moment in time that these events present in support of our common interest in nurturing innovation for health in Africa and across the world.

PRIX GALIEN INTERNATIONAL

GALIEN FoRUm

The Prix Galien medal was designed by Albert

de Jaeger (1908 – 1992), laureate of the

Premier Grand Prix de Rome architectural

prize. De Jaeger designed medals for

prominent figures such as Pope Pius

XII (at the Villa Medicis, 1937)

and Pope Jean-Paul I, Presidents

Dwight D. Eisenhower and

John F. Kennedy, distinguished

military leaders including

Marshals Leclerc, Koenig,

Montgomery, Marshall and Joukov; the

Weizmann Institute, as well as numerous artists,

literary figures and prominent personalities

such as Sacha Guitry, Marcel Proust, Henri de

Montherlant, Paul Harris, a number of Nobel

Prize laureates, the Empress of Iran SA Farah

Diba, Princess Grace of Monaco, and others…

De Jaeger is also the architect of numerous

outstanding monuments in France and

throughout the world.

THE MEDAL by ALbERT DE JAEGER

The Prix Galien recognizes outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments.

The Prix Galien was created in 1970 in honor of Galien, the father of medical science and modern pharmacology.

Worldwide the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

INNOVATION TO IMPROVE THE HUMAN CONDITION

The Prix Galien is more than an award: it is a movement with a mandate to foster, recognize and reward excellence in scientific innovation to improve the state of human health. Building on an unrivaled network of top biomedical scientists including Nobel Laureates in medicine, the Prix Galien manages an independent, cross functional and geographically diverse program of events and sponsorships to brand “the bestof the best” in new medicines and diagnostics.

Our scope is global, and our commitment to progress in medicine is both measurable and concrete. Our members express this through the establishment of productive relationships to build lasting bridges between the commercial research enterprise and local communities engaged in public policy, science, finance,academic research and the media.

In addition to recognizing advances in promising therapies, the Prix Galien’s annual Pro Bono Humanum Award for humanitarian achievements brings a unique focus to the intersection between science, business and politics. The outcome we seek is guided by the synthesis principle that underpins the conduct of science itself: successful innovation where financing, physical assets, knowledge and skills are combined from many sources to move new ideas quickly “from the bench to thebedside,” on behalf of patients everywhere.

A truly global program present in 14 countries* Our program includes a review of contributions from a new generation of innovators representing diverse sectors in health across 14 countries*. Our themes: better cross-cultural contacts, harmonized regulation, internal business process improvements, new information technologies and effective public-private partnerships can remove barriers to the commercialization of good medicines and expand access to thesebenefits to all who need them.

2018 will represent a new and exciting stage in the evolution of the Prix Galien as the pre-eminent “force populaire” behind theglobal scientific enterprise. With the support of our sponsoring organizations, our efforts willextend to all who see medical innovation not

only as an industrial policy asset but as a source of social progress – where private enterprise and public engagement combine todeliver a greater public good.

We invite all communities with a commitment to the conduct and promotion of life sciencesinnovation to contribute to this important work.

* Belgium, Canada, China, France, Germany, Greece,

Italy, Netherlands, Poland, Russia, Spain, Switzerland,

United Kingdom and the United States.

OuR mIssION:

Over the years they Participatedin the Elie Wiesel Foundation’s Conferences:

NObEl lAUREATEs

Peter Agre (Chemistry, 2003)Zhores I. Alferov (Physics, 2000)Philip W. Andersen (Physics, 1997)Kenneth J. Arrow (Economics, 1976)Robert J. Aumann (Economics, 2005)Richard Axel (Medicine, 2004)Günter Blobel (Medicine, 1999)Paul D. Boyer (Chemistry, 1997)Aaron Ciechanover (Chemistry, 2004)John M. Coetzee (Literature,, 2003)Claude Cohen-Tannoudji (Physics, 1997)Paul J. Crutzen (Chemistry, 1995)Robert F. Curl Jr. (Chemistry, 1996)His Holiness the Dalai Lama (Peace, 1989)Johann Deisenhofer (Chemistry, 1988)Richard R. Ernst (Chemistry, 1991) Sir Martin J. Evans (Medicine, 2007)John B. Fenn (Chemistry, 2002)Val Logsdon FItch (Physics, 1980) Donald A. Glaser (Physics, 1960)Sheldon Glashow (Physics, 1979)Roy Glauber (Physics, 2005)Paul Greengard (Medicine, 2000)David J. Gross (Physics, 2004)Richard F. Heck (Chemistry, 2010)James. J. Heckman (Economics, 2000)Alan J. Heeger (Chemistry, 2000)Dudley R. Herschbach (Chemistry, 1986)Avram Hershko (Chemistry, 2004)Roald Hoffman (Chemistry, 1981)Gerardus ‘t Hooft (Physics, 1999)Eric Kandel (Physiology or Medicine, 2000)Daniel Kahneman (Economics, 2002)Aaron Klug (Chemistry, 1982) Walter Kohn (Chemistry, 1998)Sir Harold W. Kroto (Chemistry, 1996)Finn E. Kydland (Economics, 2004)Yuan T. Lee (Chemistry, 1986)Jean-Marie Lehn (Chemistry, 1987)

Mairead Corrigan Maguire (Peace, 1976)Rudolph A. Marcus (Chemistry, 1992)Eric Maskin (Economics, 2007)Daniel L. McFadden (Economics, 2000)Craig C. Mello (Medicine, 2006)Robert C. Merton (Economics, 1997)James A. Mirrlees (Economics, 1996)Mario Molina (Chemistry, 1995)Luc Montaigner (Medicine, 2008)Robert A. Mundell (Economics, 1999)Ferid Murad (Medicine, 1998)Sir Vidiadhar Surajprasad Naipaul (Literature, 2001)Ei-ichi Negishi (Chemistry, 2010)Erwin Neher (Medicine, 1991) Marshall W. Nirenberg (Medicine, 1986)Shimon Peres (Peace, 1994)Edmund Phelps (Economics, 2006)John C. Polanyi (Chemistry, 1986)Stanley B. Prusiner (Medicine, 1997)José Ramos-Horta (Peace, 1996)Norman F. Ramsey (Physics, 1989)Robert C. Richardson (Physics, 1996)Richard J. Roberts (Medicine, 1993)Oscar Arias Sánchez (Peace, 1997) Thomas C. Schelling (Economics, 2005)George F. Smoot (Physics, 2006)Wole Soyinka (Literature, 1986)Joseph E. Stiglitz (Economics, 2001)Joseph H. Taylor (Physics, 1993) William David Trimble (Peace, 1998)Harold E. Varmus (Medicine, 1989) Martinus JG Veltman (Physics, 1999)Klaus von Klitzing (Physics, 1985)Elie Wiesel (Peace, 1986)Torsten Wiesel (Medicine, 1981)Betty Williams (Peace, 1976)Oliver E. Williamson (Economics, 2009)Kurt Wüthrich (Chemistry, 2002)

NOTAblEs

Palestinian Authority

Président Mahmoud Abbas

King Abdullah II and

Queen Rania of Jordan

Kofi Annan

First Lady Laura Bush

Pete Cashmore

King Juan Carlos 1st of Spain

President Bill Clinton

First Lady Hillary Clinton

George Clooney

John De Gioia

Renee Fleming

Amanda Forysth

Richard Gere

Tom Hanks

President Mikhail Gorbachev

Jeff Greenfield

Vartan Gregorian President of Irlande, Michael D. Higgins

Marvin Kalb

Ted Koppel

Nicholas Kristof

Bernard Kouchner

Maurice Levy

President Nelson Mandela

First minister of Israël Ehud Olmert

Itzhak Perlman

Nathalie Portman

Julia Roberts

President of France, Nicolas Sarkozy

Ismail Serageldin

John Silber

Sting

Uma Thurman

Oprah Winfrey

Pinchas Zukerman

Elie Wiesel and his wife, Marion, established The Elie Wiesel Foundation for Humanity soon after he was awarded the 1986 Nobel Prize for Peace. The Foundation’s mission, rooted in the memory of the Holocaust, is to combat indifference, intolerance and injustice through international dialogue and youth-focused programs that promote acceptance, understanding and equality.

The international conferences of The Elie Wiesel Foundation for Humanity serve as a catalyst for change and action. The conferences, which focus on themes of Peace, Education, Health, the Environment and Terrorism, serve to bring together Nobel Laureates and world leaders to discuss social problems and develop suggestions for change. The Foundation hosted its inaugural conference, Facing the 21st Century: Threats & Promises, in 1988 gathering 79 Nobel Laureates in Paris.

The Conference paved the way for a series of conferences including: The Anatomy of Hate; Tomorrow’s Leaders; The Future of Hope; and the Petra Conferences of Nobel Laureates.

In the United States, the Foundation has for 25 years offered the Ethics Essay Contest which challenges college juniors and seniors to analyze the urgent ethical issues confronting them in today’s complex world. For more than 20 years, the Foundation has operated two Beit Tzipora Centers for Study and Enrichment in Israel.

These Centers, in Ashkelon and Kiryat Malachi, focus on educating the Ethiopian-Jewish community and giving Ethiopian-Israeli students the opportunity to participate fully in Israeli society. Close to one thousand boys and girls are currently enrolled in after-school programs that serve as a model for other schools.

On July 2nd, 2016, Professor Elie Wiesel passed away. Today, Mrs. Marion Wiesel and the Foundation continue his work.

“ Sometimes, we must interfere.

When human lives are endangered, when human dignity is in jeopardy, national borders and sensitivities become irrelevant. Wherever men or women are persecuted because of their race, religion, or political views, that place must - at that moment - become the center of the universe.”

– Elie Wiesel from his Nobel acceptance speech.

Outreach from the Galien Foundation is under way to West African universities dedicated to medical and pharmacy training, as well as broader health and economic studies. The Foundation is requesting that each university send 10 of their most promising students to the inaugural Galien Africa Forum, which will take place at the Palais Des Congres in Dakar, Senegal on November 27 & 28, 2018.

The Forum will take place over two days, with the program built around the theme: “The Ethics and Values of Medicine and Pharmacy”. Speakers include Nobel Laureates and world-renowned scientific, industry, and policy leaders from within Africa and across the globe, all of whom will participate in highly interactive sessions that engage the audience.

Facing the 21st Century:Threats and Promises Paris, 1988

The Future of Hope:Hiroshima, 1995

Anatomy of Hate:Boston, 1989 Haifa, 1990Oslo, 1990Moscou, 1991New York, 1992

Tomorrow’s leaders:Venice, 1995Boston, 2000Dublin, 2014

Petra Conferencesof Nobel laureates:Petra, Jordan 2005, 2006, 2007, 2008

Past Conferencesof the EWF:

DAy 1:Features intimate, highly interactive thematic workshops addressing ethical questions underpinning such topics as drug pricing, access to health care, disease prevention, and open-access research. The content and format of bringing together global leaders and students in small groups draw on the rich outcomes of the Tomorrow’s Leaders Conferences, organized by the Elie Wiesel Foundation over the past decade.

DAy 2:Will bring all Forum participants together for plenary sessions that synthesize the previous day’s workshop discussions and build toward a thoughtful roadmap for the future, with particular focus on African innovation and leadership for development.

universal access To essenTial and oTHers medicines

addressinG cHronic malnuTriTion

Scientific Program co-chairS:

françoise Barré-Sinoussi Ph.D., Nobel Laureate, Director of the Regulation of Retroviral Infections Division and Professor at the Institut Pasteur in Paris, France

hon. awa marie coll-Seck MD, Minister of State, Republic of Senegal

Medicines for basic infectious and non-communicable diseases are a staple element of health provision – without them, many conditions become harder to prevent and more expensive to treat. Access to these medicines are also a sign of a well-functioning health system able to minimize costly acute care interventions with measures to keep patients with chronic conditions stable and compliant over long periods of time. In spite of this evidence, the World Health Organization (WHO) estimates that one-third of Africa’s 1.2 billion people lack access to the 433 drugs and vaccines in its latest 20th Essential Medicines List, most of which are off-patent generics in widespread use for decades in the US and Europe. Eliminating this gap would, according to the WHO, save 10 million lives worldwide every year, with the Africa region benefiting the most. Explanations for the failure to raise access to essential medicines vary, but the main factors appear to be weak health infrastructure; distribution bottlenecks at the wholesaler and pharmacy levels, especially at the “last mile” to the waiting patient; poor regulation of sub-standard, falsified and

counterfeit medicines; and patient inability to pay. While the role that patented medicines play in limiting access is often cited as well, only a handful of medicines on the WHO List are proprietary. Many such products are included in voluntary drug donation programs administered by the big multinational drug companies; some companies have waived the right to exclusivity for their patented medicines in the poorest countries. In September 2017, a WHO medicines access project launched in 2012 in 15 sub-Saharan African countries with support from the European Union (EU) completed its work with a report citing significant improvements in the region’s pharmaceutical supply chain, particularly for products for HIV, malaria and TB. Also cited were faster registration of essential medicines by local regulatory authorities and progress toward the commitment to universal health coverage as a basic right of citizenship. In this panel, participants will assess the current state of medicines access in Africa, linked to the WHO Essential Drug List benchmark; identify ways to eliminate barriers to cooperation among various public and private stakeholders

in improving the region’s performance toward universal access to essential drugs; and discuss access issues around the increasingly important field of diagnostics, where preparation of the first WHO essentials list is underway. Finally, the group will highlight additional novel partnering agreements focused on emerging non-communicable diseases like cancer, which now kills 60 per cent more Africans each year than malaria; deaths from cancer in Africa are slated to rise by 70 per cent to 2030. The Africa Access Initiative (AAI), a joint NGO and private-sector initiative launched last year by Seattle-based BioVentures for Global Health jointly with Pfizer, Takeda Pharmaceuticals, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the African Organization for Research and Training on cancer (AORTIC), is one prominent – and promising – example. AAI will pool expertise and resources of each partner with the initial goal of supplying important, life-saving chemotherapy drugs to cancer patients in five countries.

FIRsT GALIEN FORUM AFRICA THE AGENDA

manaGinG inFecTious diseases & Pandemics

Infectious and other preventable diseases remain the leading causes of death in sub-Saharan Africa. Top of the list of killers is respiratory infections, followed by HIV/AIDS and diarrheal disease. A major NCD, stroke and CVD, now ranks fourth on the list, while TB and malaria have been pushed down to fifth and sixth, respectively. The point is communicable diseases continue to dominate the health landscape in the region. The continent is a focal point for the transmission of infectious micro-organisms from animals to humans, which accounts for about 75 per cent of the diseases that have emerged as public health threats in recent years, including HIV, influenza and the deadly Ebola and Marburg viruses. Mass migrations of people displaced by political and military unrest has also contributed to the outbreak of pandemics due to the impact this has had on the capacity of local institutions to respond to the health needs of these vulnerable populations. The 2014 Ebola outbreak in Liberia, Sierra Leone and Guinea – which killed more than 11,000 people – exposed serious gaps in Africa’s preparedness to handle diseases with the potential to spread globally if not controlled. This emergency, when combined with the slow-burning toll imposed on Africa by the spread of HIV, has spurred demand for a more effective regional and international response. While there are positive precedents like President George W. Bush’s Emergency Plan for AIDS Relief (PEPFAR) – which celebrates its 15th year in 2018, raising the number of Africans receiving anti-retroviral therapy from 50,000 in 2003 to 13.3 million at present – there is a consensus that a more systemic approach is needed. The Ebola crisis revealed that existing pandemic response mechanisms were tardy, uncoordinated and massively under-resourced, particularly in the availability of trained emergency responders. In the last two years, work has commenced in several areas to address the problem, including the

introduction of improved disease surveillance capabilities; the integration of pandemic preparedness planning as a component of development aid; and increased funding for basic public health infrastructure – the first line of defense against the spread of infectious pathogens. In August 2016, the WHO revised its anti-pandemic operations in a single integrated Emergency Health Program with an improved line of sight to ground-based coordination and support. Last year, the World Bank, with support from Japan and Germany, established a Pandemic Emergency Facility to unlock funds to prioritize the response to health emergencies, in real time. On the NGO front, at the 2017 World Economic Forum in Davos, the Bill and Melinda Gates Foundation donated $100 million for the launch of the Coalition for Epidemic Preparedness Innovations (CEPI), a joint public-private venture which over the next five years plans to speed development of new vaccines to treat existing transmissible pathogens like Ebola while investing in new technologies to counter future threats. The UK-based Wellcome Trust is also involved, along with major vaccine companies like J&J and a number of leading government aid donors. Panelists will discuss the progress in executing around these and other new initiatives to address pandemic diseases in the Africa region. Improved mobilization of local resources, especially retaining scarce human capital in the fields of epidemiology, health provision and logistics, will be analyzed along with recommendations to improve government partnering with the private sector, including biopharma and vaccine manufacturers. Participants will apply their unique perspectives to answer the essential question: are the right incentives in place for a truly integrated approach to pandemic surveillance, preparedness and control in the Africa region, the front-line of defense in the global war against infectious disease?

Food and nutrition are critical to human development, especially during the formative years when much of an individual’s physical and cognitive potential is determined, with important consequences for health status later in life. Stunted growth in children under age five caused by chronic malnutrition, together with the adverse medical consequences of rising rates of young adult obesity, has thus emerged as a key public health agenda item for African countries. The topic is particularly urgent in light of the fact that Africa’s population is destined to double in size by 2050, to 2.5 billion people. In November 2017, the WHO Regional Office for Africa published its first Africa Nutrition Report, which called for urgent action to reduce malnutrition in the 47 countries surveyed, noting that one of every three children under age five in the world with stunted growth lives in Africa. It also documents a sharp rise in obesity – the number of African children classified as overweight increased by 50 percent between 2000 and 2015. Both trends carry numerous adverse consequences for public health, ranging from increased susceptibility for childhood killer diseases like malaria and TB to higher rates of debilitating long-term chronic conditions like hypertension and diabetes, which are already proliferating throughout the region at near-epidemic rates. There are also disincentives to consumer access to healthy non-processed foods from urbanization, environmental pressures on agricultural land use, and producer subsidies that distort normal market signals. Members of the panel will discuss the link between food production and sustainable agriculture practices; the effects of population growth on the food supply; the need for better information and data on the extent of malnutrition in vulnerable groups like children under age five, women of reproductive age, and the elderly; educational campaigns to fight obesity; and the distribution effects of some multilateral food aid programs. Facilitating more cross-regional and multi-functional partnerships involving field-based organizations is another topic that could be discussed.

françoise Barre-Sinoussi - Nobel prize for Medicine 2007 - Pasteur InstitutSalim S. abdool Karim - Epidemiologist - Caprisa (Center for the AIDS Program of Reserarch in South Africa)John Kengsong - Director - Centre for Disease Control and Prenvention (CDC) - South AfricaSouleymane mboup - CEO - IRESSEF (Institute for Health Research, Epidemiological Surveillance and Training)nicolas meda - Minister of Health - Burkina Faso

Denis Broun - Head of Government Affairs - Ciplaraymonde g. Koffi - Previous Minister for Health - Ivory CoastPaul Lalvani - Dean and Director, Empower School of Health, IndiaLelio marmora - Excecutive Director - UNITAID mabigue ngom - Regional Director UNFPA WCAROmartha Smit - Partner Fasken

ole Dibba-Wadda - Human Capital Department Director, African Developement Bankmarie Pierre Poirier - Regional Director UNICEF WCAROPape abdoulaye Seck - Minister of Agriculture, SenegalSalimata Wade - Nutritionist - Nutrition and Diet Association in Senegal

THe HealTH consequences oF climaTe cHanGe

wHicH Plan For non communicable diseases?

Chronic non-communicable diseases (NCDs) are a by-product of development, so it is no surprise that their incidence is growing rapidly in Africa. According the WHO Regional Office, the region will see a 27 per cent increase in the four major categories of NCDs – CVD, cancer, chronic respiratory conditions and Type II diabetes – over the next 10 years. This is the highest rate of expansion in NCDs in the world, and is largely a consequence of factors from outside the health sector such as urbanization, trade, economic conditions, and lifestyle choices involving physical exercise, nutrition and tobacco and alcohol use. The result is that a transition is underway in which the traditional emphasis on health interventions to attack communicable diseases linked to poverty must be accompanied by a much broader, multi-faceted set of policies for NCDS. In fact, by 2030 the number of deaths in Africa attributable each year to NCDs will exceed deaths from infectious, communicable conditions. This means that priorities of governments in the region will need to change, with a greater emphasis on primary care, prevention, early diagnosis, and out-patient treatment – all of which require in turn costly investments in infrastructure, people and resources that pose a significant challenge to the financing of public health systems. More attention also has to be paid to the management of disability and co-morbidities. And doing that demands better information of patient health status over the long-term based on strategies that emphasize a grassroots, community-driven approach to the overall well-being of the patient, otherwise known as population health. Panelists will reflect on the elements of a comprehensive strategy for NCDs, taking into account the nine targets contained in the WHO’s 2020 Global Action Plan on NCDs. How to harness the potential of private industry, NGOs and other community-based groups in treating the “whole patient” is another theme, along with making the case for more funding for screening, diagnostics, drugs and medical devices that can be used in both urban and rural settings. Progress in defining, collecting and applying statistics of NCD issues that can be shared among governments as a basis for informed policy-making will be reviewed as well.

Although Africa contributes little to the global build-up of greenhouse gases that cause climate change, the region is likely to suffer more than other regions on the public health and development front. According to the WHO, some 250,000 additional deaths annually due to rising sea and ground temperatures will occur worldwide between 2030 and 2050 – with African children under the age of five among the most vulnerable. Malaria, dengue, sleeping sickness and other infectious diseases are prevalent on the sub-continent and very sensitive to changes in temperature patterns. Most governments lack the health infrastructure and resources to cope with an accompanying surge in non-communicable cardiovascular and respiratory ailments as well as increased malnutrition among high-risk populations like women, children and migrants due to lower harvests of key crops caused by heat and drought.

Recognizing the threat, all 50 of the region’s countries have ratified the 2016 Paris Agreement committing to specific emissions reduction targets around the UN 1997 Framework Convention on Climate Change. However, execution around the Agreement’s commitments will be difficult for African governments without technical expertise and funding from the UN, the G-7 and other aid donors.

In this session, panelists will review current evidence as to the disease state, epidemiological, social welfare and demographic impacts of climate change in Africa and recommend initiatives to fill the education/information/advocacy, financial resource and partnership gaps needed to build local capacity to manage the challenge.

FIRsT GALIEN FORUM AFRICA THE AGENDA

wHicH HealTH insurance For THe aFrican conTinenT?

Private-sector is a $35 billion market in sub-Saharan Africa, with at least half of it financed directly by patients through out-of- pocket payments to providers. Governments, donor agencies and independent experts agree that increased access to care depends on expanded financing through private, pre-paid group insurance schemes to supplement self-pay by the wealthy and public- sector delivery of services to the poor. However, growth of the overall health insurance market has been stymied by regional variations in licensing and regulatory standards as well as the weak financial stability of schemes due to unreliable information on risk exposures, including high claims to renewal ratios. This in turn has made the regional insurance market less attractive to Western investors with experience in covering large populations with a diversity of health conditions. Recently, however, a coalition of international development organizations have committed to invest significant resources to achieve universal basic health coverage for all Africans, including extending successful precedents

on private and community-based insurance schemes in South Africa, Namibia, Rwanda, Ghana and Senegal. In August 2016, the World Bank’s International Development Association (IDA), the Global Fund, the WHO and the Africa Development Bank pledged $24 billion over the next three to five years toward this objective. The hope is that this broad, region-wide initiative to boost infrastructure will encourage more private and venture capital investment to create health insurance products for the local market. Panelists will explore gaps in regulation and business practice that discourage investments in health insurance, particularly for a growing middle-class willing to spend discretionary income on health; how to address the needs of the low income and indigent populations, in line with fiscal realities; technical improvements in risk adjustment and the re-insurance market; and facilitating more partnerships to share risks and promote best practices and country learnings, for the benefit of the entire region.

FinancinG aFrica’s HealTHcare

Africa has a resource gap in health characterized by the lack of physical plant – infrastructure – as well as the human capital required to make productive use of the resources it has. Capacity in health lags far behind demand for health services, creating a vicious cycle in which the growing burden of disease thwarts the productivity gains necessary to ensure future growth in living standards and GDP – the “health is wealth” effect.

Adding to the challenge are the pressures on public financing of health care from competing domestic and national security priorities as well as declining foreign aid disbursements. According to Deloitte’s annual Africa Construction Trends 2017 report, there is very little large-scale investment in health care: only 0.3 per cent of the total value of the region’s infrastructure projects focused on health, far behind energy/power and transport, at 21 and 16 per cent, respectively. On the private-sector front, investors in health care assets face a complex regulatory environment; scalability problems due to siloed geographies; weak

capital markets, marked by limited debt financing; and exposure to financial and political risk, from a lack of due diligence to troubles finding trustworthy local partners. Another factor is the failure to stimulate the forces of entrepreneurship that exist at the grassroots in every country. This makes it hard to foster more community engagement among key stakeholders like hospitals, physicians, and drug manufacturers to drive the development of more locally sourced products and services linked to the concept of “frugal,” needs appropriate innovations.

An active private-sector role in health infrastructure investment is vital if Africa is to see progress against the combined burden of communicable and non-communicable disease, the incidence of which will grow as the region’s population doubles over the next few decades. There is unanimous agreement among governments that public initiatives alone will not be enough to deliver the health capacity patients at every level of income should be entitled to expect. Nevertheless, private sector financing vehicles like venture capital (VC)

remain limited, as evidenced by the fact that the World Bank’s International Finance Corporation (IFC) is still the biggest investor in private-sector health care in Africa today.

Given the continued challenges to funding health care infrastructure, the Forum panel will work to define priorities to drive the allocation of investment capital over the next five years. A set of recommendations to improve the incentives for mobilization of private investment, from both domestic and foreign sources, will be discussed, along with best practices to spur more partnerships among key financial stakeholders – multilateral lending facilities, NGOs, philanthropic foundations, governments, sovereign wealth funds and others. Finally, panelists will examine progress in creating infrastructure in pharmaceutical regulation, manufacturing and supply chain logistics in the pharmaceutical sector and what other actions should be taken to stimulate growth in what is forecast to be a market worth as much as $60 billion annually by 2020.

Scientific Program co-chairS:

françoise Barré-Sinoussi Ph.D., Nobel Laureate, Director of the Regulation of Retroviral Infections Division and Professor at the Institut Pasteur in Paris, France

hon. awa marie coll-Seck MD, Minister of State, Republic of Senegal

gargee gosh - Director of Development Policy and Finance - Bill & Melinda Gates Foundationabdoulaye Diouf Sarr - Minister of health, Senegal

mame thierno Dieng - Minister of the Environment - Senegaltedros adhanom ghebreyesus - WHO Director GeneralJean Paul moatti - CEO - IRD (French Research Institute for Development)

awa marie coll Seck - Minister of Health - Senegal Bernard colombo - Chairman - Roche Diagnosticmatshido moeti - Regional Director WHO Africa Stanley okolo - Directeur General OOAS

The Prix Galien USA Committee, a group of highly accomplished individuals from the scientific and research communities, will judge which among the candidates, independent of any category, is the Best Pharmaceutical Agent (i.e. small molecule), is the Best Biotechnology Product and which is the Best Medical Technology approved by the FDA in the past ten years. As few as one or as many as three prizes may be awarded in each of these categories, and from time to time the committeemay decide on awards hors prix. The prizes are awarded for products and agents that improve the human condition.

An uNRIVALED REPuTATION FOR INTELLECTuAL RIGOR AND INTEGRITY…

Elie Wiesel, Peace Nobel Laureate;BAN Ki-moon, General Secretary, United Nations;

Bill Clinton & Philippe Douste-Blazy, 2010 Prix Galien Pro Bono Humanum Award Laureate

Born in 131AD, Galen (Galien in French) is considered the father of modern medicine and pharmacology.As an anatomist, physiologist, clinician and researcher, his work formed the basis of a school of thought known as “Galenism”, which dominated medicine until the Renaissance. In fact, Galen’s works were used as primarymedical reference for nearly two centuries.

Raised in Pergamos, he studied in Smyrna, Corinth, and Alexandria, the three centers of medical excellence in the ancient world. Legend has it that Galen was visited by Aesclapius in a dream and that this

inspired the direction of his life. When he was 17, Galen worked as a physician to the gladiatorial school. At the age of 37, Marcus Aurelius summoned him to Rome, where he grew in reputation and stature as a healer, teacher, researcher and writer. His ideas on the functioning of the human body were so well received that he became the personal doctor of young Commodus, the heir to the Emperor. He died in 201AD. During his long and eminent career, Galen completed over five hundred learned works addressing anatomy, physiology, pathology, medical theory and practice, and many forms of therapy. He traveled throughout the

world, studying local plants and remedies, eventually describing 473 original drugs and many substances of mineral and vegetable origin. Importantly, Galen was the first to codify the art of preparing active drugs using multiple ingredients. Galen’s faculties of observation, logic and deduction made him the true successor of Hippocrates, and his declaration that the primary aim of medicine was patient care formed the very cornerstone of modern pharmacy.To quote Jean-Pierre Changeux, “Galen first showed that our mind was in the brain, not in our hearts.” It can be said that this was thebeginning of experimental medicine.

Who was Galien?

Margaret A. Hamburg, MDFormer Commissioner

U.S. Food and Drug Administration

Sachin H. Jain, MD, MBAChief Medical information

and innovation officer Merck and Co.;

Lecturer in Healthcare Policy Harvard Medical

School

William N. Hait, MD, PhD

Global Head, Researchand DevelopmentJanssen Research

& Development

Paul Greengard, PhDNobel Laureate

Professor of Molecular and Cellular Neuroscience

Rockefeller University

Eric R. Kandel, MDNobel Laureate

Professor of Physiologyand Cellular Biophysics

Columbia University;Director Bio-technology

Study Center, NYU School of Medicine

Bengt Samuelsson, MD, PhD

Nobel LaureateFormer President

Karolinska InstituteFormer ChairmanNobel Foundation

Michael Rosenblatt, MD Chief Medical Officer

Flagship Ventures

Dr Morgan ShengVice President

Neuroscience Genentech

George A. Scangos, PhDChief Executive Officer

Biogen Idec

Guido RasiExecutive Director

European MedicinesAgency

Laurie Glimcher, MDCEO and President

Dana Farber Cancer Institute;

Professor of MedicineHarvard Medical School

Ezekiel Emanuel, MD, PhDVice Provost for Global

Initiatives; Chair,Dept. of Medical Ethicsand Health Policy Levy

University Professor Perelman School of Medicine and The

Wharton School, University of Pennsylvania

Joseph GoldsteinNobel Laureate

Professor of Molecular Genetics and Internal

MedicineUT, Southwestern Medical

Center at Dallas

Kenneth C. FrazierChaiman, CEO and

President,Merck

Dr Alex GorskyChaiman and CEO

Johnson & Johnson

Maria C. Freire, PhD President & Executive

DirectorFoundation for the National

Institutes of Health

Mark McClellan, MD, PhDDirector

Duke-Robert J. Margolis Center for Health Policy;

Professor of Business, Medicine, and Health Policy

Duke University

Joel S. MarcusChairman, CEO & Founder

Alexandria Real Estate Equities /

Alexandria Venture Investments; Co-Founder

Alexandria Summit

Dr Ira MellmanVice President

Research Genentech

Donald Lloyd-JonesChairman, Departmentof Preventive Medicine

Northwestern University

John LechleiterChairman and CEO

Eli Lilly & Cie

Dr Jeffrey LeidenChairman, President

and CEOVeritex

Tara Narula, MD, FACCMedical Contributor“CBS This Morning”

Steven H. Stein, MDSenior Vice President

US Clinical Development& Medical Affairs

Novartis Oncology US

Marc Tessier-Lavigne PhDPresident

Stanford University

Elias ZerhouniPresident, Global R&D

Sanofi

Krishna Yeshwant, MDGeneral Partner

Google Ventures

George Yancopoulos, MD, PhD

Chief Scientific Officer Regeneron Pharmaceuticals

President, Regeneron Laboratories

Bert VogelsteinProfessor

Johns Hopkins Medical School

P. Roy VagelosM.D., Retired Chairman

and CEO, Merck & Co., Inc.Chairman of the Board,

Regeneron Pharmaceuticals

Mikael Dolsten, MD, PhDPresident, Worldwide

Research and Development Pfizer

Richard Axel, MDNobel Laureate

Co-directorKavli Institute

for Brain Science, Columbia University

Medical Centre

Cori Bargmann PhDRockefeller University

Michael S. BrownNobel Laureate

Professor of Molecular Genetics and Internal

MedicineUT Southwestern Medical

Center at Dallas

Rory CollinsCo-director

University of OxfordClinical Trials Unit

Dr Samantha BuddVice President

Neuroscience iMed,AstraZeneca R&D

Michael BloombergFormer Mayor

City of New York

AmONG THE PREVIOus GALIEN FORum sPEAKERs

PCO France : Regimedia 17 Rue de Seine92100 Boulogne BillancourtTel : + 33 1 72 33 91 15

PCO Senegal : Africa Global Residence WaterfrontRoute de la corniche

Dakar – Senegal

COMMITTEE PRIX GALIEN INTERNATIONAL*

CHAIR Susan DESMOND-HELLMANN M.D., M.Ph. Chief Executive Officer of the Bill & Melinda Gates Foundation. Seattle, WA - USA

Belgium - Luxemburg - Romain LEFEBVRE Full professor of pharmacology at Ghent University, Ghent University, PhD Pharmacology

Canada - Dre Jean GRAY Emeritus Professor - Continuing Medical Education - Medicine and pharmacology - University of Dalhousie

France - Jean-Louis PRUGNAUD Member, National Academy of Pharmacy; Pharmaceutical Expert Consultant in Biotherapy; Former Chief Pharmacist, AP-HP (public hospital system of Paris); Member, former AMM Commission (market authorization); and Past President, Gene & Cell Therapy Commission

Germany - Erland ERDMANN University of Cologne | UOC -Division of Cardiology, Pneumology, Angiology and Intensive Care - Köln

Greece - Aristeidis A. N. PATRINOS National Technical University of Athens Ph.D. Northwestern University. Senior Vice President for Corporate Affairs in Synthetic Genomics Inc (SGI). member of the committee for the Economic and Environmental Impacts of Increasing Biofuels Production of the U.S. National Academy of Science, of the U.S. DOE exascale computer team, of the American Association for the Advancement of Science, the American Meteorological Society

Italy - Pier Luigi CANONICO Full Professor of Pharmacology, Università del Piemonte Orientale Amedeo Avogadro

The Netherlands - Jan DANSER Professor of Pharmacology and heads the Division of Pharmacology within the Pharmacology and Vascular Medicine Sector of the Department of Internal Medicine at the Erasmus MC. Rotterdam

Poland - Cezary SZCZYLIK Polish professor of medical science specializing in oncology, hematology and internal diseases

Russia - Vladimir TROFIMOVITCH President of Russian Gastroenterological Association

Switzwerland - Christoph RENNER Prof. Dr. med. - Haematology - General Internal Medicine - Medical Oncology

UK - Sir Michael RAWLINS Chair of MHRA and founding Chair of NICE

* The Prix Galien International Committee is composed of chairs from the member nations.

A record of leadership in bringing the best of biomedical discovery to the attention of the world…

The Prix Galien is a welcome initiative to stimulate creative research and promote excellence.Barack Obama - 2008

“

”

The Prix Galien since 1970 is dedicated to promoting the research and development of the medicine

and medicine industries.Macky Sall - 2018

“

”

I welcome you to the annual Prix Galien awards for innovative excellence in biomedical products and health technologies.

The awards are among the highest honors in science and commerce.Jimmy Carter - 2017

“

”

The Prix Galien is a prestigious award, a magnificent occasion to pay recognition to our researchers and to encourage our industry.

Jean Chretien - 1994

“

”

I know the importance of the Prix Galien which rewards every year therapeuticinnovations and research

works among the most creative.Emmanuel Macron - 2018

“

”

I am particularly grateful to receive this award. Bill Clinton - 2010

“”

The Prix Galien is the right event, on the right issue at the right time. I thank the Galien Foundation for bringing us together and for recognizing

that a healthier world is a safer world and a more just world.BAN Ki-moon - 2010

“

”

It is a pleasure to congratulate all those who promote the Prix Galien and pharmaceutical research: they play a vital role in the fight against disease

throughout the world.John Major - 1996

“

”